drugset / Trial / NCT07390383
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Phase 2
Recruiting
110 enrolled
Nanjing Leads Biolabs Co.,Ltd
Peking University Cancer Hospital & Institute · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
Timeline
- Start
- 2026-04-13
- Primary completion
- 2028-05-30
- Completion
- 2028-05-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LBL-024 for Injection | Unknown | — | Intravenous |
| Comparator | Tislelizumab Injection | Unknown | — | Intravenous |
| Background | Capecitabine tablets | Unknown | — | Oral |
| Background | Oxaliplatin injection | Unknown | — | Intravenous |